Official Journal
of the European Union

EN
L series

2026/2566

20.11.2026

COMMISSION IMPLEMENTING DECISION (EU) 2026/2566

of 19 November 2026

repealing Commission Implementing Decision (EU) 2026/1089 postponing the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products ([1]), and in particular Article 14(5) thereof,

After consulting the Standing Committee on Biocidal Products,

Whereas:

(1) Medetomidine was approved as an active substance for use in biocidal products of product-type 21 by Commission Implementing Regulation (EU) 2015/1731 ([2]) until 31 December 2022 subject to the conditions set out in the Annex to that Regulation.

(2) On 27 June 2021, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of medetomidine for use in biocidal products of product-type 21.

(3) Commission Implementing Decision (EU) 2022/1495 ([3]) postponed the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 to 30 June 2025, in order to allow sufficient time for the examination of the application. Commission Implementing Decision (EU) 2025/953 ([4]) further postponed the expiry date of that approval to 30 June 2026, and Commission Implementing Decision (EU) 2026/1089 ([5]) postponed again the expiry date to 31 December 2026.

(4) Commission Implementing Decision (EU) 2026/2567 ([6]) did not renew the approval of medetomidine for use in biocidal products of product-type 21 since medetomidine does not fulfil the conditions laid down in Article 12(1) of Regulation (EU) No 528/2012.

(5) Therefore, it is appropriate to repeal Implementing Decision (EU) 2026/1089,

([1]) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.
([2]) Commission Implementing Regulation (EU) 2015/1731 of 28 September 2015 approving medetomidine as an active substance for use in biocidal products for product-type 21 (OJ L 252, 29.9.2015, p. 33, ELI: http://data.europa.eu/eli/reg_impl/2015/1731/oj).
([3]) Commission Implementing Decision (EU) 2022/1495 of 8 September 2022 postponing the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 234, 9.9.2022, p. 26, ELI: http://data.europa.eu/eli/dec_impl/2022/1495/oj).
([4]) Commission Implementing Decision (EU) 2025/953 of 23 May 2025 postponing the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2025/953, 23.5.2025, ELI: http://data.europa.eu/eli/dec_impl/2025/953/oj).
([5]) Commission Implementing Decision (EU) 2026/1089 of 20 May 2026 postponing the date of expiry of the approval of medetomidine for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2026/1089, 22.5.2026, ELI: http://data.europa.eu/eli/dec_impl/2026/1089/oj).
([6]) Commission Implementing Decision (EU) 2026/2567 of 19 November 2026 not renewing the approval of medetomidine as an active substance for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2026/2567, 20.11.2026, ELI: http://data.europa.eu/eli/dec_impl/2026/2567/oj).

HAS ADOPTED THIS DECISION:

Article 1

Implementing Decision (EU) 2026/1089 is repealed.

Article 2

This Decision shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Done at Brussels, 19 November 2026.

For the Commission
The President
Ursula VON DER LEYEN